MissionIR's  Instablog

Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
My blog:
MissionIR Blog
  • CytRx Corp. (CYTR) Demonstrating Aldoxorubicin's Potential As Viable Cancer Treatment, Says Trading Coach 0 comments
    Nov 20, 2013 2:15 PM | about stocks: CYTR

    CytRx, a biopharm research and development company specializing in oncology, was recently covered in an article by SeekingAlpha contributor John Mylant who discusses recent data that demonstrates the potential of CytRx' aldoxorubicin as a substitute for commonly used doxorubicin. Mylant is the founder and CEO for OptionsWeekly.org and a long-time trading coach.

    To read the entire article visit seekingalpha.com/article/1848951

    Aldoxorubicin is an improved formulation of doxorubicin, a widely used chemotherapy drug. CytRx recently released interim clinical data from a phase 2b trial in which aldoxorubicin was compared to doxorubicin for the first-line treatment of soft tissue sarcomas (NYSEMKT:STS).

    To summarize, results show that patients administered aldoxorubicin were able to tolerate 3.5 times the standard dose of doxorubicin with fewer side effects, resulting in greater positive response to treatment.

    "The recent results from the phase 2b trial reinforces the possibility that aldoxorubicin could one day replace doxorubicin," writes Mylant.

    He also notes that at the end of September, CytRx was debt-free with approximately $23 million in short-term investments and cash equivalents.

    "As with most companies in the biotech field, when the company is in research and has not yet brought a "product to the market," it relies on raising investment capital continue to operate. I am encouraged by the interim clinical trial results to date and am optimistic for the additional phase 2b trial data which the company expects to report in December. As the company gets closer to FDA approval of aldoxorubicin, I would expect to see the share price increase in value as most biotech companies do," said Mylant in conclusion.

    For more information, visit cytrx.com

    MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com

    Stocks: CYTR
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.